FDA Grants Fast Track Designation to Atea’s AT-752 for Dengue
Atea Pharmaceuticals received Fast Track designation from the FDA for AT-752 in the treatment of dengue virus infection, a mosquito-borne disease that occurs in tropical and subtropical areas.
AT-752 is an orally administered antiviral derived from the company’s purine nucleotide prodrug platform. A prodrug is a medication or compound that is metabolized in the body into a pharmacologically active drug.
The investigational prodrug treatment works by impairing the dengue viral polymerase which plays an important role in replication of the virus.
In preclinical studies, AT-752 showed potent activity against all dengue serotypes. The drug candidate is currently in phase 2 clinical development.